Теоретические основы создания вакцины для лечения атеросклероза

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Автор, на основании своего опыта работы в области изучения морфо- и патогенеза атеросклероза, с учетом анализа литературы, представил свое видение проблемы профилактики и лечения атеросклероза. В настоящее время нельзя отрицать того, что без учета тех глубоких сдвигов в иммунной системе, которые происходят в процессе болезни, невозможно разрабатывать стратегию лечения атеросклероза. Основываться только на показателях уровня липидов в крови, назначая терапию пациенту, это значит вернуться в XX век. Но, с другой стороны, разработка современных патогенетически обоснованных методов лечения атеросклероза требует создания новой методологии, на основе которой возможна разработка вакцины против атеросклероза.

Об авторах

В. А. Нагорнев

ГУ «Научно-исследовательский институт экспериментальной медицины РАМН»

Автор, ответственный за переписку.
Email: medaj@eco-vector.com

Академик РАМН

Россия, Санкт-Петербург

Список литературы

  1. Нагорнев В. А. Патогенез атеросклероза. СПб.: Хромикс, 2006.
  2. Afek A., Harats D., Roth A. et al. Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice // Exp. Mol. Pathol. 2004. Vol. 76. P. 219-223.
  3. Aikawa M. et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro // Circulation. 2001. Vol. 103. P. 276-283.
  4. Ameli S., Hultgardh-Nilsson S., Regnstrom J, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits // Arterioscler. Thromb. Vase. Biol. 1996. Vol. 16. P. 1074-1079.
  5. Arkin M. R., and Wells J. A. Small-molecule inhibitors of protein interaction: progressing towards the dream // Nat. Rev. Drug. Discov. 2004. Vol. 3.P. 301-317.
  6. Asadullah K., Sterry W. and Volk H. D. Interleukin-10 therapy-review of a now approach // Pharmacol. Rev. 2003. Vol. 5 5. P. 241-269.
  7. Baetz A., Frey M., Heeg K., and Dalpke A. H. Supressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells // J. Biol. Chem. 2004. Vol. 279. P. 54708-54715.
  8. Barter P, Rye К A. Cholesterol ester transfer protein: its role in plasma lipid transport // Clin. Exp. Pharmacol. Physiol. 1994. Vol. 21. P. 663-672.
  9. Beutler B., Hoebe K., Georgel P. et al. Genetic analysis in innate immunity: identification and function of the TIR adapter proteins // Adv. Exp. Med. Biol. 2005. Vol. 560. R 29-39.
  10. Binder C. J., Horkko S., Dewan A. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL // Nat. Med. 2003. Vol. 9. R 736-743.
  11. Binder С. J. et al. The role of netural antibodies in atherogenesis // J. Lipid. Res. 2005. Vol. 46. P. 1353-1363.
  12. Bjorkbacka H., K unjathoo V. K, Moore K. J. et al. Reduction atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways // Nat. Med. 2004. Vol. 10. P. 416-421.
  13. Bogdan C., and Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10 // Ann. NY Acad. Sci. USA. 1993. Vol. 685. P. 713-739.
  14. Bourcier T., Sukhova G., and Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in hum an atherosclerosis // J. Biol. Chern. 1997. Vol. 272. P. 15817-15824.
  15. Brand K., Page S., Rogier G. et al. Activated transcription factor nuclear factor-kappa В is present in the atherosclerotic lesion // J. Clin. Invest. 1996. Vol. 97. P. 1715-1722.
  16. Brown M. L., Inazu A., H ester С. B. et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins //Nature. 1989. Vol. 342. P. 448-451.
  17. Burns K. et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failutr to recruit IRA K -4 // J. Exp. Med. 2003. Vol. 197. P 263-268.
  18. Caligiuri G., Rudling M., Ollivier V, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low -density lipoproteins in apolipoprotein E knockout mice // Mol. Med. 2003. Vol. 9. P. 10-17.
  19. Chen Y. et al. Peripheral deletion of antigen-reactive T cells in oral tolerance // Nature. 1995. Vol. 376. P. 177-180.
  20. Chuang T. H., and Ulevitch R. J. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors // N at. Immunol. 2004. Vol. 5. P. 495-502.
  21. Chyu K. Y. et al. Timing affacts the efficacy of LDL immunization on atherosclerotic lesions in apo Е(~Л) m ice // Atherosclerosis. 2004. Vol. 176. P. 27-35.
  22. Constant S. L., and Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the aiternative approaches // Ann. Rev. Immunol. 1997. Vol. 15. P. 297-322.
  23. Cunha E Q., Moncada S., Liew E Y Interleukin-10 (IL -10) inhibits the induction of nitric oxide synthase by interferon-y in murine macrophages // Biochem. Biophys. Res. Commun. 1992. Vol. 182. P 1155-1159.
  24. Daugherty A., Rateri D. T lymphocytes in atherosclerosis. The Yin-Yang of Th1 and Th2 influence on lesion formation // Circ. Res. 2002. Vol. 90. P 1039-1040.
  25. DiChiara M. R., Kiely J, M., Gimbrone M. A. et al. Inhibition of E-selectin gene espression by transforming growth factor beta in endothelial cells involves coactivator integration of smad and nuclear factor kappaB-mediated signals // J. Exp. Med. 2000. Vol. 192. P 695-704.
  26. Divanovic S. et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105 // Nat. Immunol. 2005. Vol. 6. P 571-578.
  27. Edfeldt K., Swedenborg J., Hansson G. К et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation // Circulation. 2002. Vol. 105. P. 1158-1161.
  28. Fong L. G., Parthasaraty S., Witztum J.L., Ste inberg D. Non enzymatic oxidative cleavage of peptide bonds in apoprotein B-100 // J. Lipid. Res. 1987. Vol. 12. P. 1466-1477.
  29. Fredrikson G. N., Soderberg L, Lindholm M. et al. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences // Arterioscler. Thromb. Vase. Biol. 2003. Vol. 23. P. 879-884.
  30. Freigang S., Horkko S., Miller E. et al. Immunization of LDL receptor-deficient mice with homologous malandialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes // Arterioscler. Thromb. Vase. Biol. 1998. Vol. 18. P 1972-1982.
  31. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease/ / Autoimmun. Rev. 2002. Vol. 1. P. 233-237.
  32. Frostegard J., Ulfgren A. K., Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (T hl) and macrophage-stimulating cytokines // Atherosclerosis. 1999. Vol. 145. P. 33-43.
  33. Fucao T. and Koyasu S. PI3K and negative regulation of TLR signaling // Trends. Immunol. 2003. Vol. 24. P. 358-363.
  34. Fucumoto M., Shoji T, Emoto M. et al. Antibodies against oxidized LDL and carotid artery intima-media thickens in a heaithy population It Arterioscler. Thromb. Vase. Biol. 2000. Vol. 20. P 703-707.
  35. George J., Afek A., Gilurd B. et al. Induction of early atherosclerosis in LDL-receptor deficient mice immunized with P2-glycoprotein 1 // 1998. Vol. 11. P 1108-1115.
  36. George J. et al. Supression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with P2-glycoprotein 1 // Cardiovasc. Res. 2004. Vol. 62. P. 603-609.
  37. Genolet R., Wahli W, and Michalik L. PPARs as drug targets to modulate inflammatory responses? // Curr. Drug. Targets Inflamm. Allergy. 2004. Vol. 3. P. 361-375.
  38. Grooth G. J., Klerkx A. H., Stroes E. S. et al. A review of CETP and its relation to atherosclerosis // J. Lipid. Res. 2004. Vol. 45. P. 1967-1974.
  39. Han J., and Ulevitch R. Limiting inflammatory responses during activation of innate immunity // Nat. Immunol. 2005. Vol. 6. P. 1198-1205.
  40. Hansen P. R., Chew M., Zhou J. et al. Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNF-a confers no additional benefit // Atherosclerosis. 2001. Vol. 15 8. P. 87-94.
  41. Hansson G. K. Vaccination against atherosclerosis. Science of fiction? // Circulation. 2002. Vol. 106. P. 337-356.
  42. Hansson G. K. Inflammation, atherosclerosis, and coronary disease // N. Engl. J. Med. 2005. Vol. 352. P. 1685-1695.
  43. Hansson G. K., and Libby P. The immune response in atherosclerosis: a double-edged sword // Nat. Rev. Immunol. 2006. Vol. 6. P. 508-519.
  44. Hansson G. K., Libby P, Shonbeck U., Yan Z. Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis // 2002. Vol. 91. P. 1281-1291.
  45. Harais D., Yacov N., Gilburn B. Oral tolerance with heat shock protein-65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet- driven atherosclerotic lesions // J. Am. Coll. Cardiol. 2002. Vol. 40. P. 1333-13 38.
  46. Hauer A. D., Uyttenhove C., de Vos P et al. Blocade of interleukin-12 function by protein vaccination attenuates atherosclerosis // Circulation. 2005. Vol. 112. P. 1054-1062.
  47. Heeschen C., Dimmeler S., Hamm C. W. The CAPTURE Study Investigators: Serum level of the anti-inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes // Circulation. 2003. Vol. 107. P. 2109-2114.
  48. Honda H. M., Leitinger N., Frankel M. et al. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites // Arterioscler. Thromb. Vase. Biol. 1999. Vol. 19. P. 680-686.
  49. Hulthe J., Wilkund O., Hurt-Camejo E., Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A2 // Arterioscler. Thromb. Vase. Biol. 2001. Vol. 21. P. 269-274.
  50. Iwami К. I. et al. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccaride signaling // J. Immunol. 2000. Vol. 165. P. 6682-6686.
  51. Janssens S., Burns K., Vercammen E. et al. MyD88S, a splice variant of MyD88, differentially modulates NF-кВ and AP-1 dependent gene expression // FEBSb Lett. 2003. Vol. 548. P. 103-107.
  52. Kotlyarov A., Neininger A., Schubert C., and Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-a biosynthesis // Nat. Cell. Biol. 1999. Vol. 1. P. 94-97.
  53. Latchman D. S. Transcription factors as potential targets for therapeutic drugs // Curr. Pharm. Biotechnol. 2000. Vol. 1. P. 57-61.
  54. Li Q., and Verma I. M. NF-кВ regulation in the immune system // Nat. Rev. Immunol. 2002. Vol. 2. P. 725-734.
  55. Liew E Y., Xu D., Brint E. K., and O ’Neill L. A. Negative regulation of toll-like receptor-mediated immune responses // Nat. Rev. Immunol. 2005. Vol. 5. P. 446-458.
  56. Loiarro M. et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1 dependent activation of NF-кВ // J. Biol. Chern. 2005. Vol. 280. P. 15809-15814.
  57. Mach E Statins as immunomodulatory agents // Circulation. 2004. Vol. 109. Suppl. //. P. 1115-1117.
  58. Mach E, Schonbeck U., Sukhova G. К et al. Reduction of atherosclerosis in mice by inhibition of CD40 signaling // Nature. 1998. Vol. 394. P. 200-203.
  59. Mallat Z., Besnard S., Duriez M. et al. Protective role of interleukin-10 in atherosclerosis // Circ. Res. 1999. Vol. 85. P. el7-e24.
  60. Maron R., Sukhova G., Faria A. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aorta arch of lowOdensity lipoprotein receptor-deficient mice //Circulation. 2002. Vol. 106. P. 1708-1715.
  61. Metz P M., DeWitt D. L., Stetler-Stevenson W G. et al. Interleukin-10 supression of monocyte prostaglandin-dependent matrix metalloproteinase production // Science. 1994. Vol. 269. P. 21322-21329.
  62. Michelsen K. S., Wong M. H., Shah P К et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. P. 10679-10684.
  63. Miller D. L., Yaron R., Yellin M. J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression // J. Leukoc. Biol. 1998. Vol. 63. P. 373-379.
  64. Monaco C., Andreakos E., Kiriakidis S. et al. Canonical pathway of nuclear factor kappa В activation selectively regulates ptoinflammatory and prothrombotic responses in human atherosclerosis // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. P. 5634-5639.
  65. Neto J. R. F. et al. Passive immunization with monoclonal (IgM) antibody accelerated atherosclerosis in vein-graft model in apo E null mice // Circulation. 2004. Vol. 110. R Ш - 52.
  66. Nilsson J., Hansson J. K., Shah P K. Immunomodulation of atherosclerosis. Implications for vaccine developm ent // Arterioscler. Thromb. Vase. Biol. 2005. Vol. 25. P. 18-28.
  67. Nilsson J., Calara F., Regnstrom J. et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after ballon in hypercholesterolemic rabbits // J. Am. Coll. Cardiol. 1997. Vol. 30. R 1886-1891.
  68. Okabe T., Kishimoto C., Shimada K. et al. Effects of late administration of immunoglobulin on experimental atherosclerosis in apolipoprotein E-deficient mice // Exp. Invest. 2005. Vol. 69. R 1543-1546.
  69. Palinski W., Witztum J. L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the developm ent of atherosclerosis // J. Intern. Med. 2000. Vol. 247. R 371-380.
  70. Palinski Ж, Miller E., Witztum J, L. Immunization of low density lipoprotein (LDL) receptordeficient rabbits with homolohous malondialde-hyde-modified LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. P. 821-825.
  71. Pinderski-Oslund L. J., Hendrick С. C., Olvera T et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo // Arterioscler. Thromb. Vase. Biol. 1999. Vol. 19. R 2847-2853.
  72. Pinderski L, J., Fischbein M, P, Subbanagounder G. et al. Overexpression of interleukin-10 by activated T lym phocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes // Circ. Res. 2002. Vol. 90. R 1064-1071.
  73. Pradier O., Gerard C., Delvaux A. et al. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide // Eur. J. Immunol. 1993. Vol. 23. R 2700—2703.
  74. Reyes O. S., Chyu К Y., Yano J. et al. Immunization with a novel hum an A po В 100 related peptide reduces atherosclerosis and inflammation in apo E null mice // 2002. Vol. 39 (Suppl. A). S. 240A.
  75. Rittershaus C., Miller D. P, Thomas L. J. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis // Atheroscler. Thromb. Vase. Biol. 2000. Vol. 20. R 2106-2112.
  76. Sattar N., McCarey D. W, Capell H., and McLnnes I. B. Explaining how «high-grade» systemic inflammation accelerates vascular risk in rheumatoid arthritis // Circulation. 2003. Vol. 108. R 2957-2963.
  77. Schipou A. et al. Recombinant human antibodies against aldegyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis // Circulation. 2004. Vol. 110. R 2047-2052.
  78. Shah R K., Chyu K-Y., Fredrikson G. IL, and Nilsson J. Immunomodulation of atherosclerosis with a vaccine // 2005. Vol. 2. R 639-646.
  79. Shaw P. X., Horkko S., Chang M. K. et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity // J. Clin. Invest. 2000. Vol. 105. R 1731-1740.
  80. Schmidt-Weber С. B. and Blaser K. Regulation and role of transforming growth factor-p in immune tolerance induction and inflammation // Curr. Opin. Immunol. 2004. Vol. 16. R 709-716.
  81. Silvestre J. S., Mallat Z., Tamarat R. et al. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis // Circ. Res. 2001. Vol. 89. R 259-264.
  82. Stemme S., Faber B., Holm J. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. R 3893-3897.
  83. Suzuki N., Suzuki S., and Yeh W. C IRAK-4 as the central TIR signaling mediator in innate immunity // Trends Immunol. 2002. Vol. 23. P. 503-506.
  84. Tall A. R. Plasma Cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies // J. Intern. Med. 1995. Vol. 237. R 5-12.
  85. Tomvall P, Waeg G., Nilsson J. et al. Auto-antibodies against modified low-density lipoproteins in coronary artery disease // Atherosclerosis. 2003. Vol. 167. R 347-353.
  86. Tupin E., Nicoletti A., Eihage R. et al. CD1- dependent activation of NKT cell aggravates atherosclerosis // J. Exp. Med. 2004. Vol. 199. R 417-422.
  87. Wesche H et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family // J. Biol. Chern. 1999. Vol. 274. R 19403-19410.
  88. Хи G., Dietrich Н., Steiner Н. J. et al. Induction of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65 // Arterioscler. Thromb. 1992. Vol. 12. P. 789-799.
  89. Xu Q., WilleitJ, Marosi M. et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis // Lancet. 1993. Vol. 341. P. 255-259.
  90. Xu X. H., Shah R X., Faure E. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL // Circulation. 2001. Vol. 104. P. 3103-3108.
  91. Yoshida M. Potential role of statines in inflammation and atherosclerosis // J. Atheroscler. Thromb. 2003. Vol. 10. P. 140-144.
  92. Youssef E, Stuve O., Patarroyo J. C. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease // Nature. 2002. Vol. 420. P. 78-84.
  93. Zhou X. H., Paulsson G., Stemme S., Hansson G. K. Hypercholesterolem ia is associated with a T helper (Th)l/Th2 swich of the autoimmune response in atherosclerotic apo E-knockout mice // J. Clin. Invest. 1998. Vol. 101. P. 1717-1725.
  94. Zhou X., Caligiuri G., Hamsten A. et al. LDL immunization induces T-cell-dependentantibody formation and protection against atherosclerosis // Arterioscler. Thromb. Vase. Biol. 2001. Vol. 21. P. 108-114.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Нагорнев В.А., 2007


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.